• Qing-Fen Zheng, Jing-Yun Zhang, Ju-Shan Wu, Ying Zhang, Mei Liu, Li Bai, Jin-Yan Zhang, Jing Zhao, Yu Chen, Zhong-Ping Duan, and Su-Jun Zheng.
• From the Artificial Liver Center, Beijing YouAn Hospital, Capital Medical University, Beijing, China (Q-F Z, J-Y Z, M L, L B, J-Y Z, J Z, Y C, Z-P D, S-J Z); Department of hepatobiliary surgery, Beijing YouAn Hospital, Capital Medical University, Beijing, China (J-S W); Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (Q-F Z); Department of Gastroenterology, The First Affiliated Hospital of Xinxiang Medical College, Weihui, China (Q-F Z); and Intensive Care Unit of Liver Disease, The 302 hospital of Chinese PLA, Beijing, China (Y Z).
• Medicine (Baltimore). 2016 Feb 1; 95 (6): e2639e2639.

AbstractPrompt and accurate prediction of the outcome is the key to make correct medical decision and to reduce the mortality in patients with HBV-related acute-on-chronic liver failure (ACLF). Increasing evidence have certified that small, noncoding microRNAs (miRNAs) play critically regulatory roles in the pathogenesis of liver diseases. However, it remains unclear whether and how miRNAs involve in the prognosis of ACLF.Microarray analysis was performed to characterize the miRNA expression profiles in liver tissues from 1 HBV-related ACLF patient and 1 matched healthy control. Nine miRNAs with at least 5 folds difference between these 2 persons were picked out. The present prospective study involving 39 HBV-related ACLF patients including 20 recovered and 19 nonrecovered patients, which include death (n = 9) and liver transplantation (n = 10). The serum expression of these miRNAs detected by quantitative real-time Polymerase Chain Reaction (qRT-RCR) was then compared between the 2 groups. Moreover, the correlation between the serum miRNAs and the prognostic indexes for ACLF was analyzed.The result of microarray analysis showed 9 miRNAs had different expression in liver tissues of ACLF patient compared with healthy control (upregulated: miRNA-130a, -21, -143, and -200a; downregulated: miRNA-486-5p, -192, -148a, -122, and -194). Unlike the expression profiles in liver tissue, 8 serum miRNAs except miRNA-194 were markedly upregulated in ACLF patients (P < 0.05). Remarkably, the serum expression of miRNA-130a and miRNA-486-5p was higher in recovered than nonrecovered ACLF patients (P < 0.05). Especially, the serum miRNA-130a was negatively correlated with international normalized ratio, prothrombin time, Model for End-Stage Liver Disease score, and positively correlated with prothrombin time activity. The AUC for recovered versus nonrecovered patients of miRNA-130a was 0.741 (P = 0.02).miRNA-130a might be a useful prognosis biomarker in patients with HBV-related ACLF.

20 keywords...

hide…